A Study of KL130008 in Adults With Severe Alopecia Areata
Study Details
Study Description
Brief Summary
The purpose of this study is to assess KL130008 is safe and effective in adults with severe alopecia areata
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
This is a multi-center Phase 2 study to evaluate the safety and effectiveness of an investigational drug in adults (≥18 years and ≤65 years) who have 50% or greater scalp hair loss, including alopecia totalis (AT) and alopecia universalis (AU).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: KL130008 capsule High Dose KL130008 capsule administered orally |
Drug: KL130008/Placebo
Drug: KL130008 Drug: Placebo
|
| Experimental: KL130008 capsule Middle Dose KL130008 capsule administered orally |
Drug: KL130008/Placebo
Drug: KL130008 Drug: Placebo
|
| Experimental: KL130008 capsule Low Dose KL130008 capsule administered orally |
Drug: KL130008/Placebo
Drug: KL130008 Drug: Placebo
|
| Placebo Comparator: Placebo Placebo administered orally |
Drug: KL130008/Placebo
Drug: KL130008 Drug: Placebo
|
Outcome Measures
Primary Outcome Measures
- Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20 [ Time Frame: Week 24 ] [Week 24]
Percentage of Participants Achieving SALT ≤ 20
Secondary Outcome Measures
- Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20 [ Time Frame: Week 36 ] [Week 36]
Percentage of Participants Achieving SALT ≤ 20
- Percent Change from Baseline in SALT score [ Time Frame: Baseline, Week 24, 36 ] [Week 24, 36]
Percent change from baseline in SALT score
- Percentage of Participants Achieving 50% Improvement of Severity of Alopecia Tool (SALT50) [ Time Frame: Week 24, 36 ] [Week 24, 36]
Percentage of participants achieving SALT50
- Percentage of Participants Achieving 75% Improvement of Severity of Alopecia Tool (SALT50) [ Time Frame: Week 24, 36 ] [Week 24, 36]
Percentage of participants achieving SALT75
- Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 10 [ Time Frame: Week 24, 36 ] [Week 24, 36]
Percentage of Participants Achieving SALT ≤ 10
- Measure for Eyebrow (EB) Hair Loss 0 or 1 with ≥2-point Improvement from Baseline [ Time Frame: Week 24, 36 ] [Week 24, 36]
EB hair loss 0 or 1 with ≥2-point Improvement from Baseline
- Measure for Eyelash (EL) Hair Loss 0 or 1 with ≥2-point Improvement from Baseline [Week 24, 36]
EL hair loss 0 or 1 with ≥2-point Improvement from Baseline
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or female subjects with the age of ≥18 and ≤ 65 years old at the time of informed consent.
-
Able to understand the procedures and methods of this study, and will to provide a signed and dated informed consent form.
-
Diagnosed alopecia areata(AA) without other reasons caused alopecia.
-
Have severe AA, as determined by all of the following:Current AA episode of more than 6 months' duration and hair loss encompassing ≥50% of the scalp, including alopecia totalis (AT) and alopecia universalis (AU);No spontaneous improvement over the past 6 months;Current episode of severe AA of less than 8 years.
-
All women of childbearing potential and all men must be willing to use at least one highly effective method of contraception from the signing of informed consent, throughout the duration of the study, and for 3 months after the last dose of investigational drugs.
Exclusion Criteria:
-
Known history of anaphylaxis to any of the ingredients and/or other similar products.
-
Participated in a clinical trial of any drug or medical device and has used an investigational product (including placebo and control group) or treatment within 1 month or 5 half-lives before randomization.
-
Previously treated with JAK inhibitors.
-
Corticosteroids, finasteride, minoxidil,topical immunotherapy treated within 8 weeks before randomization.
-
Diphenylcyclopropenone (DPCP), HMGCoA reductase inhibitor, Chinese herbal medicine treated within 4 weeks before randomization.
-
With other diseases: acute "diffuse" type of AA, lymphoproliferative disease, tumor, severe chronic gastrointestinal disease, thyroid disorders, serious cardiovascular disease.
-
Subjects with evidence of clinical laboratory abnormalities at screening that, in the opinion of the investigator, may affect the safety of subjects or the interpretation of study results: Hemoglobin level < 10.0 g/dL. Absolute white blood cell (WBC) count /absolute neutrophil count (NEUT)/absolute lymphocyte count(LYMPH)<LLN. Aspartate aminotransferase (AST), or alanine aminotransferase (ALT) > 2 × ULN, total bilirubin(TBIL)>1.5 × ULN. QTcF> 450ms. Subjects with eGFR ≤ 60 mL/min based on Cockcroft-Gault calculation.
-
The subject had or currently has a severe infection, and had a severe infection judged by the investigator within 1 month before randomization: HBV, TP-Ab, HIV, HCV, TB positive.
-
Subjects who are unsuitable to the trial, as identified by the investigator.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The First Affiliated Hospital of Sun Yat-sen University | Guangzhou | Guangzhou | China | 510080 |
Sponsors and Collaborators
- Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Investigators
- Principal Investigator: Xingqi Zhang, First Affiliated Hospital, Sun Yat-Sen University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- KL223-II-05
- CTR20221881